Experimental Dentifrice Remineralization/Fluoride Uptake in an in Situ Model

Inclusion Criteria

• Age: Aged between 18 and 78
• Fluoride: Currently living in the Indianapolis area which has a fluoridated water supply (1 ppm F) and not taking fluoride supplements for medical reasons
• Dentures: Currently wearing a removable mandibular partial denture with sufficient room in the posterior buccal flange area to accommodate two enamel specimens (required dimensions 12 x 7 mm). Willing and capable of wearing their removable partial dentures 24 hours per day during the experimental periods
• Dental health: Have no current active caries or periodontal disease that may compromise the study or the health of the participants and all restorations in a good state of repair
• Salivary flow: Have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 mL/min; gum base stimulated whole saliva flow rate ≥ 0.8 mL/min
• Compliance: Understands and is willing, able and likely to comply with all study procedures and restrictions
• Consent: Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form
• General Health: Good general health with (in the opinion of the investigator) no clinically significant and/or relevant abnormalities of medical history or oral examination that could interfere with participant safety during the study period

Exclusion Criteria

• Antibiotics: Currently taking antibiotics or have taken antibiotics in the two weeks prior to the screening visit
• Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients
• Pregnancy: Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
• Breast-feeding:Women who are breast-feeding.
• Clinical Study/Experimental Medication: Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit
• Personnel: An employee of the sponsor or the study site who is directly involved in the study